We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent investor discussions regarding Aviva Plc (AV) reflected a mix of positive sentiment and cautious observations, particularly concerning Aviva's stock performance and upcoming corporate developments. Notably, several analyst upgrades have been made, with Deutsche Bank and HSBC raising Aviva's price target to 565 pence. One investor quoted, “This stock has a strong yield now hovering around 6.5%, making it attractive for income-seeking investors.” Meanwhile, the company's share price remained resilient, hovering around a 10-year high, prompting speculation about its potential impact on the ongoing acquisition of Direct Line Group (DLG), with one user pondering, “Why are DLG shares stuck around 268p?”
Discussions also highlighted the complexities surrounding corporate pension fund strategies in the context of potential legislative changes, which could affect investor outlook. Comments on government proposals to utilize pension fund surpluses underlined a sense of uncertainty, with one participant stating, “In principle I am in favor of a rebalance of the pension funds investments, but I expect any changes to take a long time,” reflecting a broader skepticism about immediate benefits for investors. Overall, the investor sentiment in this forum suggests a balance between optimism about Aviva's recent upgrades and lingering concerns about external economic and regulatory factors that may influence its stock performance moving forward.
Show more
In the week leading up to February 2, 2025, several key developments have emerged regarding Aviva PLC, particularly concerning its stock positions as reported under the Takeover Code regulations. UBS O'Connor, BlackRock Group, BNP Paribas, Barclays PLC, and State Street Global Advisors all filed disclosures highlighting that they hold interests in Aviva PLC securities representing 1% or more. Notably, UBS O'Connor reported their position as of January 29, 2025, while other entities such as BlackRock and BNP Paribas provided similar 1% disclosures for the same date. These disclosures reflect heightened interest in Aviva's stock, likely influenced by strategic movements in the broader insurance and financial sectors.
On the same date, Morgan Stanley also disclosed dealings in relation to Aviva as part of their client-serving activities, reinforcing the engagement of major financial institutions with Aviva's market positioning. The continuous influx of positional disclosures indicates that Aviva PLC remains a focal point of interest among institutional investors amidst emerging market dynamics. These developments suggest a potentially shifting landscape for Aviva's capital structure and investor confidence, particularly as they prepare for the competitive environment expected in 2025 and beyond.
Show more
Since two major UK insurance companies announced takeover terms on 6 December – a “possible̶ |
Paying possibly a little more may have discouraged other possible suiters to make offers ?? |
No spud, if it was cheap then maybe a good deal. They played too nicely and got squeezed; they should have been doing the squeezing.It will balance after a couple of years, but this board need to remember they work for the shareholders. |
If the T/O of DLG goes through OK and leverage increases a tad it's a better use of funds in my mind than being leveraged in to having to support Govt sponsored small caps with requisit support musterred by Rachel R! |
Imo the bid going through and the dilution in the av price is largely already in todays price. There is a small discount for the execution risk offset by the upside potential if the deal falls apart. |
Anyone any ideas/guesses where the share price will be on the official bid? Also taking into account the dilution? |
Spud, you are not alone on the DLG deal. I prefer Aviva to grow their long term revenues through PRT and the private health businesses. I see these as excellent long term robust revenues with lower short term impact from local & world events… however, impressed with Amanda and plan to keep my holding long term with adding on occasions GLA |
Sir Clive Cowdery set for bumper windfall on £8.3bn sale of insurance firm Resolution Life to Japanese rival |
I surely can't be the only cynical one regarding the potential DLG acquisition can I?spud |
A firm offer (assuming one is to be made) must be made by 25/12. They've got Santa working on it. |
Are there any indications on the timetable for the next takeover steps ? |
The risk is it doesn't happen. I'm keeping my Aviva stock |
*JEFFERIES RAISES AVIVA PRICE TARGET TO 560 (550) PENCE - 'BUY' |
That’s a good position to be in! Nicely done |
Rightly or wrongly, I've sold out of av. today and kept my dlg. |
I'd agree, but they're looking for more acquisitions, which will need funding.I do not see dividends going higher, I see capital growth. |
I have no doubt that buybacks are off the table for the next two to three years given the use of capital to finance the acquisition. That said, given that EPS is set to get a double digit uplift post the acquisition I do not see any reason to expect the dividend per share to not continue to grow. |
Thanks - some interesting reading. |
Aviva boss Amanda Blanc seeks more takeover targets after Direct Line deal |
The article mentioned in post 20457 :- |
Cardinal, the good bit is 18 months or so away, for now it means diddly squat. A pay now (lower share price) reap later (bigger dividend).They have overpaid in my opinion; they played nicely. All this, and the CMA can stick their oar in when it goes to them.Don't get me wrong, the BOD had to do something as the sediment was starting to settle, plus there's further reporting that they are open to more acquisitions.Patienc |
The basic question for me is how will I, as an AV shareholder, benefit from this takeover. Cost synergies will presumably be spelled out in the prospectus but what about the risk to the dividend a long drawn out CMA review and possibility of rejection due to market share. |
The basic question for me is how will I, as an AV shareholder, benefit from this takeover. Cost synergies will presumably be spelled out in the prospectus but what about the risk to the dividend a long drawn out CMA review and possibility of rejection due to market share. |
Cross selling opportunities are overrated usually driven by the marketing dept. The key in motor will be a continual focus on cost reduction. If they just by the book and kill off the rest then this could be a good deal. |
Sunday Times "Drivers on hold in mega merger" " Dial M for Merger" |
Type | Ordinary Share |
Share ISIN | GB00BPQY8M80 |
Sector | Insurance Carriers, Nec |
Bid Price | 514.00 |
Offer Price | 514.20 |
Open | 515.00 |
Shares Traded | 4,017,705 |
Last Trade | 16:29:55 |
Low - High | 512.60 - 517.00 |
Turnover | 41.43B |
Profit | 1.09B |
EPS - Basic | 0.4052 |
PE Ratio | 12.69 |
Market Cap | 13.75B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads